Fresh From the Bench: Latest Precedential Patent Case
Contributed by Schwabe Williamson & Wyatt. Originally published on Patexia; republished here as part of the LexDana archive.
CASE OF THE WEEK
Netflix, Inc. v. DivX, LLC, Appeal Nos. 2022-1203, -1204 (Fed. Cir. Oct. 25, 2023)
In its only precedential patent opinion this week, the Federal Circuit issued a cautionary note to petitioners in inter partes reviews. Specifically, the Court affirmed a decision by the Patent Trial and Appeal Board that ruled a patent not invalid based on arguments as the Board understood them. Netflix asserted the Board had misunderstood the arguments. The Federal Circuit, however, found that the Board made no errors in understanding the Petition as framed, and thus found against Netflix.
The patents in this case concerned methods for adaptive bitrate streaming of content on playback devices (mobile phones or computers). The details of the patents are beyond what is necessary to understand the import of the Board’s decision. For present purposes, one of the claims at issue recited a “filtering” step, which involves filtering a list of assets (media streams), followed by a “generating” step, wherein a top-level index file is generated. Netflix argued in its petition that the “filtering” limitation was satisfied by a piece of prior art’s (“Pyle’s”) reference to a pre-existing manifest, and that the “generating” step was satisfied by Pyle’s reference to a new manifest.
Editors:
Nika Aldrich, IP Litigation Group Leader, Schwabe, Williamson & Wyatt, P.C.
Jason A. Wrubleski, Shareholder
More insights
Fresh From the Bench: Latest Precedential Patent Case
Ridge Corp. et al. v. Kirk NationaLease Co. et al. , Appeal No. 2025-1254 (Fed. Cir. July 13, 2026) In its only precedential patent opinion last week, the Federal Circuit considered an appeal of a preliminary injunction issued by the U.S. District Court…
Fresh From the Bench: Latest Precedential Patent Cases
CASE OF THE WEEK Wyeth LLC v. AstraZeneca Pharmaceuticals LP , Appeal No. 2024-2325 (Fed. Cir. July 9, 2026) In our Case of the Week, the Federal Circuit affirmed a district court ruling reversing a $107.5 million jury verdict against AstraZeneca in a case…
Enanta Pharmaceuticals, Inc. v. Pfizer Inc., Appeal No. 2025-1427 (Fed. Cir. Jun. 23, 2026)
CASE OF THE WEEK Enanta Pharmaceuticals, Inc. v. Pfizer Inc., Appeal No. 2025-1427 (Fed. Cir. Jun. 23, 2026) In our Case of the Week, the Federal Circuit affirmed summary judgment invalidating all claims of Enanta’s Patent No. 11,358,953 as…